# The Use of MMC During PRK and Its Effect on Postoperative Topical Steroid Requirements

> **NCT02030990** · PHASE2,PHASE3 · UNKNOWN · sponsor: **United States Naval Medical Center, San Diego** · enrollment: 300 (estimated)

## Conditions studied

- Corneal Opacity

## Interventions

- **DRUG:** Mitomycin-C
- **DRUG:** Fluorometholone 1% topical ocular steroid

## Key facts

- **NCT ID:** NCT02030990
- **Lead sponsor:** United States Naval Medical Center, San Diego
- **Sponsor class:** FED
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-08
- **Primary completion:** 2023-01
- **Final completion:** 2023-07
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2022-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02030990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02030990, "The Use of MMC During PRK and Its Effect on Postoperative Topical Steroid Requirements". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02030990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*